Literature DB >> 26931315

Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.

Marjorie Roques1, Marie Lorraine Chretien1,2, Camille Favennec1, Ingrid Lafon1, Emmanuelle Ferrant1, Caroline Legouge1, Alexia Plocque1, Camille Golfier1, Laurence Duvillard3, Lucie Amoureux4, Jean Noel Bastie1,2, Lory Maurin-Bernier5, Frederic Dalle6, Denis Caillot1,2.   

Abstract

Unlike bacterial infections, the value of procalcitonin (PCT) in detecting fungal infections in leukaemia patients is not clear. To determine whether the monitoring of PCT coupled with C-reactive protein (CRP) and fibrinogen (Fib) could be helpful in the management of pulmonary aspergillosis (IPA) or mucormycosis (PM), we retrospectively analysed the evolution of PCT, CRP and Fib levels in 94 leukaemia patients with proven/probable IPA (n = 77) or PM (n = 17) from D-12 to D12 relative to IFI onset defined as D0. Overall, 2140 assays were performed. From D-12 to D0, 12%, 5% and 1.4% of patients had PCT >0.5, 1 and 1.5 μg l(-1) , respectively, while CRP was >50, 75 and 100 mg l(-1) in 84%, 70% and 57% and Fib was >4, 5 and 6 g l(-1) in 96%, 80% and 61% of cases respectively (P < 10(-7) ). The same trends were observed from D1 to D12. Overall, between D-12 and D12, only 6.4% of patients had PCT >1.5 μg l(-1) , while CRP >100 mg l(-1) and Fib >6 g l(-1) were observed in 80% and 75% of cases respectively (P < 10(-7) ). In leukaemia patients, IPA or PM was accompanied by a significant increase in CRP and Fib while PCT remained low.
© 2016 Blackwell Verlag GmbH.

Entities:  

Keywords:  Procalcitonin; aspergillosis; leukaemia; mucormycosis; neutropenia

Mesh:

Substances:

Year:  2016        PMID: 26931315     DOI: 10.1111/myc.12487

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Histopathologically Confirmed Pulmonary Mucormycosis as a Complication of COVID-19: a Case Report from Romania and Insight into Pathology.

Authors:  George Sebastian Gherlan; Maria Cristina Hoara; Sebastian George Smadu; Corneliu Petru Popescu; Petronela Ionescu; Simin-Aysel Florescu
Journal:  Maedica (Bucur)       Date:  2022-03

2.  Severe extensive community acquired aspergillus infection in a full-term infant accompanied with increases in white blood cell counts and C-reactive protein: a case report.

Authors:  Yanli Wang; Wenjing Chen; Wenshen Wu; Dongling Yu; Huiheng Yan; Xiuzhen Ye
Journal:  BMC Pediatr       Date:  2021-03-09       Impact factor: 2.125

Review 3.  Complementary Roles of Short and Long Pentraxins in the Complement-Mediated Immune Response to Aspergillus fumigatus Infections.

Authors:  Raffaella Parente; Valentina Possetti; Marco Erreni; Francesca D'Autilia; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani; Antonio Inforzato; Andrea Doni
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

4.  The Clinical Value of Procalcitonin in the Neutropenic Period After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Meng Shan; Danya Shen; Tiemei Song; Wenyan Xu; Huiying Qiu; Suning Chen; Yue Han; Xiaowen Tang; Miao Miao; Aining Sun; Depei Wu; Yang Xu
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

5.  COVID-19-associated pulmonary aspergillosis is associated with increased in-hospital mortality and prolonged SARS-CoV-2 viral shedding.

Authors:  Jhong-Ru Huang; Hsiao-Chin Shen; Chuan-Yen Sun; Wei-Chih Chen; Yuh-Min Chen; Jia-Yih Feng; Kuang-Yao Yang
Journal:  J Formos Med Assoc       Date:  2022-08-08       Impact factor: 3.871

Review 6.  Host Soluble Mediators: Defying the Immunological Inertness of Aspergillus fumigatus Conidia.

Authors:  Sarah Sze Wah Wong; Vishukumar Aimanianda
Journal:  J Fungi (Basel)       Date:  2017-12-24

7.  Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Authors:  Jörg Janne Vehreschild; Philipp Koehler; Frédéric Lamoth; Juergen Prattes; Christina Rieger; Bart J A Rijnders; Daniel Teschner
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.